Skip to main content
SpringerLink
Log in
Book cover

Cardiac Allograft Rejection pp 197–232Cite as

Clinical Diagnosis and Management of Cardiac Allograft Rejection and Maintenance Immunosuppression

  • Chapter

  • 72 Accesses

Abstract

Despite improvements in immunosuppression, cardiac rejection accounts for substantial morbidity and mortality following cardiac transplantation (Table 1). In the Cardiac Transplant Research Database (CTRD) studies, the mean cumulative number of treated rejection episodes per patient was 0.8, 1.10, and 1.3 at 3, 6, and 12 months post-transplant, repectively (Figure 1A).1,2 Actuarial freedom from first treated rejection episode was 39% at 6 months and 37% at 12 months (Figure IB). Overall, more than 90% of all rejection episodes occur in the first six months post-transplant.3

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kobashigawa J, Kirklin J, Naftel D, et al. Pretransplantation Risk Factors for Acute Rejection after Heart Transplantation: A Multiinstitutional Study. J Heart Lung Transplant 1993;12:355–66.

    PubMed  CAS  Google Scholar 

  2. Jarcho J, Naftel D, Shroyer T, et al. Influence of HLA mismatch on rejection after heart transplantation: A multiinstitutional study. J Heart Lung Transplant 1994;13:583–96.

    PubMed  CAS  Google Scholar 

  3. Miller L. Long-term complications of cardiac transplantation. Prog Cardiovasc Dis 1991;33:229–82.

    Article  PubMed  CAS  Google Scholar 

  4. Zerbe T, Arena V, Kormos R, Griffith B, Hardesty R, Duquesnoy R. Histocompatibility and other risk factors for histological rejection of human cardiac allografts during the first three months following transplantation. Transplantation 1991;52:485–90.

    Article  PubMed  CAS  Google Scholar 

  5. Grattan M, Moreno-Cabral C, Starnes V, Oyer P, Stinson E, Shumway N. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561–6.

    Article  PubMed  CAS  Google Scholar 

  6. Winters G, Costanzo-Nordin M, O’Sullivan E, et al. Predictors of late acute orthotopic heart transplant rejection. Circulation 1989;80 (suppl III):III-106–III-110.

    Google Scholar 

  7. Miller L, Schlant R, Kobashigawa J, Kubo S, Renlund D. Task Force 5: “Complications” in 24th Bethesda Conference, Cardiac Transplantation. J Amer Coll Cardiol 1993;22:41–54.

    Article  CAS  Google Scholar 

  8. Renlund D, Gilbert E, O’Connell J, et al. Age-associated decline in cardiac allograft rejection. Am J Med 1987;83:391–8.

    Article  PubMed  CAS  Google Scholar 

  9. Kubo S, Naftel D, Mills R, et al. Risk factors for late recurrent rejection after heart transplantation: A multiinstitutional, multivariable analysis. J Heart Lung Transplant 1995;14:409–18.

    PubMed  CAS  Google Scholar 

  10. Gallo P, Agozzino L, Angelini A, et al. Causes of late failure after heart transplantation: A ten-year survey. J Heart Lung Transplant 1997;16:1113–21.

    PubMed  CAS  Google Scholar 

  11. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: Seventeenth Official Report-2000. J Heart Lung Transplant 2000;19:909–31.

    Article  PubMed  CAS  Google Scholar 

  12. Hosenpud J, Bennett L, Keck B, Fiol B, Novick R. The registry of the International Society for Heart and Lung Transplantation: Fourteenth Official Report-1997. J Heart Lung Transplant 1997;16:691–712.

    PubMed  CAS  Google Scholar 

  13. McGriffin D, Kirklin J, Naftel D, Bourge R. Competing outcomes after heart transplantation: a comparison of eras and outcomes. J Heart Lung Transplant 1997;16:190–8.

    Google Scholar 

  14. Bourge R, Naftel D, Costanzo-Nordin M, et al. Pretransplantation risk factors for death after heart transplantation: A multiinstitutional study. J Heart Lung Transplant 1993;12:549–62.

    PubMed  CAS  Google Scholar 

  15. Stevenson L, Miller L. Cardiac transplantation as therapy for heart failure. Current Problems in Cardiology 1991; April: 221–305.

    Google Scholar 

  16. Little R, Kay G, Epstein A, et al. Arrhythmias after orthotopic cardiac transplantation: Prevalence and determinants during initial hospitalization and late follow-up. Circulation 1989;80 (suppl III):III-140–III-146.

    Google Scholar 

  17. Pavri B, O’Nunain S, Newell J, Ruskin J, Dec G. Prevalence and prognostic significance of atrial arrthythmias after orthotopic cardiac transplantation. J Amer Coll Cardiol 1995;25:1673–80.

    Article  CAS  Google Scholar 

  18. Scott C, Dark J, McComb J. Arrhythmias after cardiac transplantation. Am J Cardiol 1992;70:1061–3.

    Article  PubMed  CAS  Google Scholar 

  19. Park J, Hsu D, Hordof A, Addonizion L. Arrhythmias in pediatric heart transplant recipients: Prevalence and association with death, coronary artery disease, and rejection. J Heart Lung Transplant 1993;12:956–64.

    PubMed  CAS  Google Scholar 

  20. Blanche C, Czer L, Trento A, et al. Bradyarrhythmias requiring pacemaker implantation after orthotopic heart transplantation: Association with rejection. J Heart Lung Transplant 1992;11:446–52.

    PubMed  CAS  Google Scholar 

  21. de Jonge N, Jambroes G, Lahpor J, Woolley S. Ventricular fibrillation during acute rejection after heart transplantation. J Heart Lung Transplant 1992; 11:797–8.

    PubMed  Google Scholar 

  22. Stinson E, Dong E, Bieber C, Schroeder J, Shumway N. Cardiac transplantation in man: Early rejection. J Amer Med Assoc 1969;207:2233–42.

    Article  CAS  Google Scholar 

  23. Yeoh T, Frist W, Eastburn T, Atkinson J. Clinical significance of mild rejection of the cardiac allograft. Circulation 1992;86 (suppl II):II-267–II-271.

    Google Scholar 

  24. Cilberto G, Mascarello M, Gronda E, et al. Acute rejection after heart transplantation: Noninvasive echocardiographic evaluation. J Am Coll Cardiol 1994;23:1156–61.

    Article  Google Scholar 

  25. Gill E, Borrego C, Bray B, Renlund D, Hammond E, Gilbert E. Left ventricular mass increases during cardiac allograft vascular rejection. J Amer Coll Cardiol 1995;25:922–6.

    Article  CAS  Google Scholar 

  26. Cilberto G, Cataldo G, Cipriani M, et al. Echocardiographic assessment of cardiac allograft rejection. European Heart Jour 1989;10:400–8.

    Google Scholar 

  27. Hauptman P, Couper G, Aranki S, Kartashov A, Mudge G, Loh E. Pericardial effusions after cardiac transplantation. J Am Coll Cardiol 1994;23:1625–9.

    Article  PubMed  CAS  Google Scholar 

  28. Dodd D, Brady L, Carden K, Frist W, Boucek M, Boucek R. Pattern of echocardiographic abnormalities with acute cardiac allograft rejection in adults: Correlation with endomyocardial biopsy. J Heart Lung Transplant 1993;12:1009–18.

    PubMed  CAS  Google Scholar 

  29. Angermann C, Nassau K, Stempfle H, et al. Recognition of acute cardiac allograft rejection from serial integrated backscatter analyses in human orthotopic heart transplant recipients: Comparison with conventional echocardiography. Circulation 1997;95:140–50.

    Article  PubMed  CAS  Google Scholar 

  30. Kemkes B, Schutz A, Engelhardt M, Brandl U, Breuer M. Noninvasive methods of rejection diagnosis after heart transplantation. J Heart Lung Transplant 1992;11:S211–31.

    Google Scholar 

  31. Haberl R, Weber M, Reichenspurner H, et al. Frequency analysis of the surface electrocardiogram for recognition of acute rejection after orthotopic cardiac transplantation in man. Circulation 1987;76:101–8.

    Article  PubMed  CAS  Google Scholar 

  32. Auer T, Schreier G, Hutten H, et al. Paced epimyocardial electrograms for noninvasive rejection monitoring after heart transplantation. J Heart Lung Transplant 1996;15:993–8.

    PubMed  CAS  Google Scholar 

  33. Wahlers T, Haverich A, Schafers H, et al. Changes of the intramyocardial electrogram after orthotopic heart transplantation. J Heart Lung Transplant 1986;5:450–6.

    CAS  Google Scholar 

  34. Warnecke H, Schuler S, Goetze H, et al. Noninvasive monitoring of cardiac allograft rejection by intramyocardial electrogram recordings. Circulation 1986;74 (suppl III):III-72–III-76.

    Google Scholar 

  35. Grauhan O, Muller J, Pfitzmann R, et al. Humoral rejection after heart transplantation: reliability of intramyocardial electrogram recordings (IMEG) and myocardial biopsy. Transplant International 1997;10:439–45.

    Article  PubMed  CAS  Google Scholar 

  36. Morocutti G, Di Chiara A, Proclemer A, et al. Signal-averaged electrocardiography and dop-pler echocardiographic study in predicting acute rejection in heart transplantation. J Heart Lung Transplant 1995;14:1065–72.

    PubMed  CAS  Google Scholar 

  37. Graceffo M, O’Rourke R. Cardiac transplant rejection is associated with a decrease in the high-frequency components of the high-resolution, signal-averaged electrocardiogram. American Heart J 1996;132:820–6.

    Article  CAS  Google Scholar 

  38. Babuty D, Aupart M, Machet M, Rouchet S, Cosnay P, Barnier D. Detection of acute cardiac allograft rejection with high resolution electrocardiography: experimental study in rats. J Heart and Lung Transplant 1996;15:1120–9.

    CAS  Google Scholar 

  39. Everett J, Palmer M, Jessurun J, Shumway S. Noninvasive diagnosis of cardiac allograft rejection in an orthotopic canine model. Ann Thorac Surg 1996;62:1337–40.

    Article  PubMed  CAS  Google Scholar 

  40. Valantine H, Yeoh T, Gibbons R, et al. Sensitivity and specificity of diastolic indexes for rejection surveillance: temporal correlation with endomyocardial biopsy. J Heart Lung Transplant 1991;10:757–65.

    PubMed  CAS  Google Scholar 

  41. Desruennes M, Corcos T, Cabrol A, et al. Doppler echocardiography for the diagnosis of acute cardiac allograft rejection. J Am Coll Cardiol 1988;12:63–70.

    Article  PubMed  CAS  Google Scholar 

  42. St. Goar F, Gibbons R, Schnitter I, Valantine H, Popp R. Left ventricular diastolic function: Doppler echocardiographic changes soon after cardiac transplantation. Circulation 1990;82:872–8.

    Article  Google Scholar 

  43. Valantine H. Rejection surveillance by doppler echocardiography. J Heart Lung Transplant 1993;12:422–6.

    PubMed  CAS  Google Scholar 

  44. Hosenpud J. Noninvasive diagnosis of cardiac allograft rejection: Another of the many searches for the grail. Circulation 1992;85:368–71.

    Article  PubMed  CAS  Google Scholar 

  45. Stempfle H, Angermann C, Kraml P, Schutz A, Kemkes B, Theisen K. Serial changes during acute allograft rejection: quantitative ultrasound tissue analysis versus myocardial histologic findings. J Amer Coll Cardiol 1993;1:310–7.

    Article  Google Scholar 

  46. Masuyama T, Valantine H, Gibbons R, Schnittger I, Poop R. Serial measurement of integrated-ultrasonic backscatter in human cardiac allografts for the recognition of acute rejection. Circulation 1990;81:829–39.

    Article  PubMed  CAS  Google Scholar 

  47. Gotteiner N, Vonesh M, Crawford S, et al. Myocardial acoustics in pediatric allograft rejection. J Heart Lung Transplant 1996;15:596–604.

    PubMed  CAS  Google Scholar 

  48. Frist W, Yasuda T, Segall G, et al. Noninvasive detection of human cardiac transplant rejection with indium-111 antimyosin (Fab) imaging. Circulation 1987;76 (suppl V):V-81–V-85.

    Google Scholar 

  49. Schuetz A, Fritsch S, Kemkes B, et al. Antimyosin monoclonal antibodies for early detection of cardiac allograft rejection. J Heart Lung Transplant 1990;9:654–61.

    CAS  Google Scholar 

  50. Ballester M, Carrio I. Noninvasive detection of acute heart rejection: the quest for the perfect test. J Nucl Cardiol 1997;4:249–55.

    Article  PubMed  CAS  Google Scholar 

  51. Schuetz A, Breuer M, Kemkes B. Antimyosin antibodies in cardiac rejection. Ann Thorac Surg 1997;63:578–81.

    Article  Google Scholar 

  52. Obrador D, Ballester M, Carrio I, et al. The diagnosis of rejection activity in the heart transplant by monoclonal antimyosin antibodies. Revista Espanola de Cardiologia 1995;48 Suppl 7:92–5.

    PubMed  Google Scholar 

  53. Ballester M, Obrador D, Carrio I, et al. Early postoperative reduction of monoclonal antimyosin antibody uptake is associated with absent rejection-related complications after heart transplantation. Circulation 1992;85:61–8.

    Article  PubMed  CAS  Google Scholar 

  54. Hesse B, Mortensen S, Folke M, Brodersen A, Aldershvile J, Pettersson G. Ability of antimyosin scintigraphy monitoring to exclude acute rejection during the first year after heart transplantation. J Heart Lung Transplant 1995;14:23–31.

    PubMed  CAS  Google Scholar 

  55. De Nardo D, Scibilia G, Macchiarelli A, et al. The role of indium-111 antimyosin (Fab) imaging as a noninvasive surveillance method of human heart transplant rejection. J Heart Lung Transplant 1989;8:407–12.

    Google Scholar 

  56. Picano E, De Pieri G, Salerno J, et al. Electrocardiographic changes suggestive of myocardial ischemia elicited by dipyridamole infusion in acute rejection early after heart transplantation. Circulation 1990;81:72–7.

    Article  PubMed  CAS  Google Scholar 

  57. Richter J, Herreros J, Serena A, Domper M, Ramirez J, Areas R. Thallium scintigraphy in human transplants: A way to detect myocardial damage. J Heart Lung Transplant 1991;10:33–7.

    PubMed  CAS  Google Scholar 

  58. Canby R, Evanochko W, Barrett L, et al. Monitoring the bioenergetics of cardiac allograft rejection using in vivo P-31 nuclear magnetic resonance spectroscopy. J Am Coll Cardiol 1987;9:1067–74.

    Article  PubMed  CAS  Google Scholar 

  59. Konstam M, Aronovitz M, Runge V, et al. Magnetic resonance imaging with gadolinium-DPTA for detecting cardiac transplant rejection in rats. Circulation 1988;78 (suppl III):III-87–111-94.

    Google Scholar 

  60. Eugene M, Lechat P, Hadjiisky P, Teillac A, Grosgogeat Y, Cabrol C. Nuclear magnetic resonance and proton relaxation times in experimental hetertopic heart transplantation. J Heart Lung Transplant 1986;5:39–45.

    CAS  Google Scholar 

  61. Aherne T, Tscholakoff D, Finkbeiner W, et al. Magnetic resonance imaging of cardiac transplants: the evaluation of rejection of cardiac allografts with and without immunosuppression. Circulation 1986;74:11–22.

    Article  Google Scholar 

  62. May R, Cooper C, Du Toit E, Reichart B. Cytoimmunologic monitoring after heart and heart-lung transplantation. J Heart Lung Transplant 1990;9:133–5.

    CAS  Google Scholar 

  63. Hanson C, Boiling S, Stoolman L, et al. Cytoimmunologic monitoring and heart transplantation. J Heart Lung Transplant 1988;7:424–9.

    CAS  Google Scholar 

  64. Fyfe A, Daly P, Galligan L, Pirc L, Feindel C, Cardella C. Coronary sinus sampling of cytokines after heart transplantation: Evidence for macrophage activation and interleukin-4 production within the graft. J Am Coll Cardiol 1993;21:171–6.

    Article  PubMed  CAS  Google Scholar 

  65. George J, Kirklin J, Naftel D, et al. Serial measurements of interleukin-6, interleukin-8, tumor necrosis factor-alpha, and soluble vascular cell adhesion molecule-1 in the peripheral blood plasma of human cardiac allograft recipients. J Heart Lung Transplant 1997;16:1046–53.

    PubMed  CAS  Google Scholar 

  66. Grant S, Lamb W, Brooks N, Brenchley P, Hutchinson I. Serum cytokines in human heart transplant recipients: Is there a relationship to rejection? Transplantation 1996;62:480–91.

    Article  PubMed  CAS  Google Scholar 

  67. Deng M, Erren M, Kammerling L, et al. The relation of interleukin-6, tumor necrosis factor-alpha, IL-2, and IL-2 receptor levels to cellular rejection, allograft dysfunction, and clinical events after cardiac transplantation. Transplantation 1995;60:1118–23.

    Article  PubMed  CAS  Google Scholar 

  68. Dengler T, Zimmermann R, Tiefenbacher C, Braun K, Sack F, Kubler W. Endothelin plasma levels in acute graft rejection after heart transplantation. J Heart Lung Transplant 1995;14:1057–64.

    PubMed  CAS  Google Scholar 

  69. Eisen H, Eisenberg S, Saffitz J, Bolman R, Sobel B, Bergmann S. Noninvasive detection of rejection of transplanted hearts with indium-111-labeled lymphocytes. Circulation 1987;75:868–76.

    Article  PubMed  CAS  Google Scholar 

  70. Volk H, Schuler S, Czerlinsi S, et al. Serum levels of soluble interleukin-2 receptor C-reactive protein, neopterin, myoglobin and light chains of cardiac myosin fail to correlate with the occurence of rejection in long-term renal and heart transplant patients. Clin Transplant 1992;6:21–6.

    Google Scholar 

  71. Hoshinga K, Wood N, Wolfgang T. Clinical usefulness of monitoring for transferrin receptor-positive circulatin lymphocytes in cardiac transplant recipients. Transplant Proc 1986;18:743–4.

    Google Scholar 

  72. Ansari A, Mayne A, Sundstrom J, et al. Frequency of hypoxanthine guanine phosphoribosyltrans-ferase (HPRT(-)) T cells in the peripheral blood of cardiac transplant recipients: a noninvasive technique for the diagnosis of allograft rejection. Circulation 1995;92:862–74.

    Article  PubMed  CAS  Google Scholar 

  73. Sobotka P, Gupta D, Lansky D, Costanzo M, Zarling E. Breath pentane is a marker of acute cardiac allograft rejection. J Heart Lung Transplant 1994;13:224–9.

    PubMed  CAS  Google Scholar 

  74. Carrier M, Russell D, Wild J, Emery R, Copeland J. Urinary polyamines as markers of cardiac allograft rejection: a clinical evaluation. J Thorac Cardiovasc Surg 1987;96:806–10.

    Google Scholar 

  75. Carrier M, Russell D, Wild J, Emery R, Copeland J. Prolactin as a marker of rejection in human heart transplantation. J Heart Lung Transplant 1987;6:290–2.

    CAS  Google Scholar 

  76. Roodman S, Miller L, Tsai C. Role of interleukin 2 receptors in immunologic monitoring following cardiac transplantation. Transplantation 1988;45:1050–6.

    Article  PubMed  CAS  Google Scholar 

  77. Goldman M, Lippman R, Landwehr D, et al. Beta 2 microglobulin and the diagnosis of cardiac transplant rejection. Transplantation 1983;36:209–11.

    Article  PubMed  CAS  Google Scholar 

  78. Zimmermann R, Baki S, Dengler T, et al. Troponin T release after heart transplantation. Br Heart J 1993;69:395–8.

    Article  PubMed  CAS  Google Scholar 

  79. Anderson J, Hossein-Nia M, Brown P, Corbishley C, Murday A, Holt D. Creatine kinase MB isoforms: a potential predictor of acute cardiac allograft rejection. J Heart Lung Transplant 1995;14:666–70.

    PubMed  CAS  Google Scholar 

  80. Gash A, Kayne F, Morely D, Fitzpatrick J, Alpern J, Brozena S. Serum myoglobin does not predict cardiac allograft rejection. J Heart Lung Transplant 1994;13:451–4.

    PubMed  CAS  Google Scholar 

  81. Isobe M, Narula J, Soughern J, Strauss H, Khaw B, Haber E. Imaging the rejecting heart: In vivo detection of major histocompatibility complex class II antigen induction. Circulation 1992;85:738–46.

    Article  PubMed  CAS  Google Scholar 

  82. von Scheidt W, Ziegler U, Kemkes B, Erdmann E. Heart transplantation: Hemodynamics over a five-year period. J Heart Lung Transplant 1991;10:342–50.

    Google Scholar 

  83. Valantine H, Appleton C, Hatle L, et al. A hemodynamic and doppler echocardiographic study of ventricular function in long-term cardiac allograft recipients: Etiology and prognosis of restrictive-constrictive physiology. Circulation 1989;79:66–75.

    Article  PubMed  CAS  Google Scholar 

  84. Mills R, Haftel D, Kirklin J, et al. Heart transplant rejection with hemodynamic compromise: A multiinstitutional study of the role of endomyocardial cellular infiltrate. J Heart Lung Transplant 1997;16:813–21.

    PubMed  CAS  Google Scholar 

  85. Zales V, Crawford S, Backer C, et al. Role of endomyocardial biopsy in rejection surveillance after heart transplantation in neonates and children. J Am Coll Cardiol 1994;23:766–71.

    Article  PubMed  CAS  Google Scholar 

  86. Santos-Ocampo S, Sekarski T, Saffitz J, et al. Echocardiographic characteristics of biopsy-proven cellular rejection in infant heart transplant recipients. J Heart Lung Transplant 1996;15:25–34.

    PubMed  CAS  Google Scholar 

  87. Neuberger S, Vincent R, Doelling N, et al. Comparison of quantitative echocardiography with endomyocardial biopsy to define myocardial rejection in pediatric patients after cardiac transplantation. American Journal of Cardiology 1997;79:447–50.

    Article  PubMed  CAS  Google Scholar 

  88. Kimball T, Semler D, Witt S, Khoury P, Daniels S. Noninvasive markers for acute heart transplant rejection in children with the use of automatic border detection. Journal of the American Society of Echocardiography 1997; 10:964–72.

    Article  PubMed  CAS  Google Scholar 

  89. Caves P, Stinson E, Billingham M, Shumway N. Percutaneous transvenous endomyocardial biopsy in human heart recipients. Ann Thorac Surg 1973;15:325–35.

    Article  Google Scholar 

  90. Williams M, Lee M, DiSalvo T, et al. Biopsy-induced flail tricuspid leaflet and tricuspid regurgitation following orthotopic cardiac transplantation. Am J Cardiol 1996;77:1339–44.

    Article  PubMed  CAS  Google Scholar 

  91. Anderson J, Marshall H. The femoral venous approach to endomyocardial biopsy: comparison with internal jugular and transarterial approaches. Am J Cardiol 1984;53:833–7.

    Article  PubMed  CAS  Google Scholar 

  92. Anderson A, Levin T, Feldman T. External jugular vein approach for percutaneous right ventricular biopsy. J Heart Lung Transplant 1997;16:576–8.

    PubMed  CAS  Google Scholar 

  93. Mills R, Young J. Chapter 35: Evaluation for cardiac transplantation and follow-up of the cardiac transplant recipient. In Diagnostic and Therapeutic Cardiac Catheterization, Second Edition, Edited by Carl Pepine, Williams and Wilkins, 1994.

    Google Scholar 

  94. Fowles R, Mason J. Endomyocardial biopsy. Ann Intern Med 1982;97:885–94.

    PubMed  CAS  Google Scholar 

  95. Bhat G, Burwig S, Walsh R. Morbidity of endomyocardial biopsy in cardiac transplant recipients. Am Heart J 1993;125:1180–1.

    Article  PubMed  CAS  Google Scholar 

  96. Fitchett D, Forbes C, Guerraty A. Repeated endomyocardial biopsy causing coronary arterial-right ventricular fistula after cardiac transplantation. Am J Cardiol 1988;62:829–31.

    Article  PubMed  CAS  Google Scholar 

  97. Deckers J, Hare J, Baughman K. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: A seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J Am Coll Cardiol 1992;19:43–7.

    Article  PubMed  CAS  Google Scholar 

  98. Billingham M, Cary N, Hammond M, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group. J Heart Lung Transplant 1990;9:587–93.

    CAS  Google Scholar 

  99. Billingham M. Dilemma of variety of histopathologic grading systems for acute cardiac allograft rejection by endomyocardial biopsy. J Heart Lung Transplant 1990;9:272–6.

    CAS  Google Scholar 

  100. Fishbein M, Bell G, Lones M, et al. Grade 2 cellular heart rejection: does it exist? J Heart Lung Transplant 1994;13:1051–7.

    PubMed  CAS  Google Scholar 

  101. Constanzo-Nordin M, Winters G, Fisher S, et al. Endocardial infiltrates in the transplanted heart: Clinical significance emerging form the analysis of 5,026 endomyocardial biopsy specimens. J Heart Lung Transplant 1993;12:741–7.

    Google Scholar 

  102. Brunner-La Rocca H, Sutsch G, Schneider J, Follath F, Kiowski W. Natural course of moderate cardiac allograft rejection (International Society for Heart Transplantation Grade 2) early and late after transplantation. Circulation 1996;94:1334–8.

    Article  PubMed  CAS  Google Scholar 

  103. White J, Guiraudon C, Pflugfelder P, Kostuk W. Routine surveillance myocardial biopsies are unnecessary beyond one year after heart transplantation. J Heart Lung Transplant 1995;14:1052–6.

    PubMed  CAS  Google Scholar 

  104. Winters G, McManus B, Pathologists RCRTT. Consistencies and controversies in the application of the International Society for Heart and Lung Transplantation working formulation for heart transplant biopsy specimens. J Heart Lung Transplant 1996;15:728–35.

    PubMed  CAS  Google Scholar 

  105. Nielsen H, Sorensen F, Nielsen B, Bagger J, Thayssen P, Baandrup U. Reproducibility of the acute rejection diagnosis in human cardiac allografts: The Stanford classification and the International grading system. J Heart Lung Transplant 1993;12:239–43.

    PubMed  CAS  Google Scholar 

  106. Fyfe B, Loh E, Winters G, Couper G, Kartashov A, Schoen F. Heart transplantation-associated perioperative ischemic myocardial injury: Morphological features and clinical significance. Circulation 1996;93:1133–40.

    Article  PubMed  CAS  Google Scholar 

  107. Nakhleh R, Jones J, Goswitz J, Anderson E, Titus J. Correlation of endomyocardial biopsy findings with autopsy findings in human cardiac allografts. J Heart Lung Transplant 1992;11:479–85.

    PubMed  CAS  Google Scholar 

  108. Sharpies L, Cary N, Large S, Wallwork J. Error rates with which endomyocardial biopsy specimens are graded for rejection after cardiac transplantation. Am J Cardiol 1992;70:527–30.

    Article  Google Scholar 

  109. Sehti G, Kosaraju S, Arabia F, Roasdo L, McCarthy M, Copeland J. Is it necessary to perform surveillance endomyocardial biopsies in heart transplant recipients? J Heart Lung Transplant 1995;14:1047–51.

    Google Scholar 

  110. McNamara D, Di Salvo T, Mathier M, Keck S, Semigran M, Dec G. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression. J Heart Lung Transplant 1996;15:506–15.

    PubMed  CAS  Google Scholar 

  111. O’Connell J, Renlund D. Variations in diagnosis, treatment, and prevention of cardial allograft rejection: the need for standardization? J Heart Lung Transplant 1990;9:269–71.

    Google Scholar 

  112. Lloveras J, Escourrou G, Delisle M, et al. Evolution of untreated mild rejection in heart transplant recipients. J Heart Lung Transplant 1992;11:751–6.

    PubMed  CAS  Google Scholar 

  113. Winter G, Loh E, Schoen F. Natural history of focal moderate cardiac allogaft rejection: Is treatment warranted? Circulation 1995;91:1975–80.

    Google Scholar 

  114. Milano A, Caforio A, Livi U, et al. Evolution of focal moderate (International Society for Heart and Lung Transplantation Grade 2) rejection of the cardiac allograft. J Heart Lung Transplant 1996;15:456–60.

    PubMed  CAS  Google Scholar 

  115. Costanzo-Nordin M. Cardiac allograft vasculopathy: Relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 1992;11:S90–103.

    PubMed  CAS  Google Scholar 

  116. Hauptman P, Nakagawa T, Tanaka H, Libby P. Acute rejection: Culprit of coincidence in the pathogenesis of cardiac graft vascular disease? J Heart Lung Transplant 1995;14:S173–80.

    PubMed  CAS  Google Scholar 

  117. Weis M, von Scheidt W. Cardiac allograft vasculopathy. Circulation 1997;96:2069–77.

    Article  Google Scholar 

  118. Gao S, Schroeder J, Alderman E, et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 1987;76 (suppl V):V-56–V-61.

    Google Scholar 

  119. Uretsky B, Murali S, Reddy P, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987;76:827–34.

    Article  PubMed  CAS  Google Scholar 

  120. Olivari M, Homan D, Wilson R, Kubo S, Ring W. Coronary artery disease in cardiac transplant patients receiving triple-drug immunosuppression. Circulation 1989;80 (suppl III):III-111–III-115

    Google Scholar 

  121. Gao S, Schroeder J, Hunt S, Valantine H, Hill I, Stinson E. Influence of graft rejeciton on incidence of accelerated graft coronary artery disease: A new approach to analysis. J Heart Lung Transplant 1993;12:1029–35.

    PubMed  CAS  Google Scholar 

  122. Stovin P, Sharpies L, Schofield P, et al. Lack of association between endomyocardial evidence of rejection in the first six months and the later development of transplant-related coronary artery disease. J Heart Lung Transplant 1993;12:100–6.

    Google Scholar 

  123. Hornick P, Smith J, Pomerance A, et al. Influence of acute rejection episodes, HLA matching, and donor/recipient phenotype on the development of “early” transplant-associated coronary artery disease. Circulation 1997;96 (suppl II):II-148–II-153.

    Google Scholar 

  124. Fornes P, Heudes D, Simon D, Guillemain R, Amrein C, Bruneval P. Influence of acute or chronic rejection on myocardial collagen density in serial endomyocardial biopsy specimens from cardiac allografts. J Heart Lung Transplant 1996;15:796–803.

    PubMed  CAS  Google Scholar 

  125. Nitenberg A, Aptecard E, Benvenuti C, et al. Effects of time and previous acute rejection episodes on coronary vascular reserve in human heart transplant recipients. J Am Coll Cardiol 1992;20:1333–8.

    Article  PubMed  CAS  Google Scholar 

  126. Anguita M, Lopez-Rubio F, Arizon J, et al. Repetitive nontreated episodes of grade IB or 2 acute rejection impair long-term cardiac graft function. J Heart Lung Transplant 1995;14:452–60.

    PubMed  CAS  Google Scholar 

  127. Miller L. Treatment of cardiac allograft rejection with intravenous corticosteroids. J Heart Lung Transplant 1990;9:283–7.

    CAS  Google Scholar 

  128. Heublein B, Wahlers T, Haverich A. Pulsed steroids for treatment of cardiac rejection after transplantation: What dosage is necessary? Circulation 1989;80 (suppl III):III-97–III-99.

    Google Scholar 

  129. Lonquist J, Radovancevic B, Vega J, et al. Reevaluation of steroid tapering after steroid pulse therapy for heart rejection. J Heart Lung Transplant 1992;11:913–19.

    PubMed  CAS  Google Scholar 

  130. Michler R, Smith C, Drusin R, et al. Reversal of cardiac transplant rejection without massive immunosuppression. Circulation 1986;74 (suppl III):III-68–III-71.

    Google Scholar 

  131. Hosenpud J, Norman D, Pantely G. Low-dose oral prednisone in the treatment of acute cardiac allograft rejection not associated with hemodynamic compromise. J Heart Lung Transplant 1990;9:292–6.

    CAS  Google Scholar 

  132. Kobashigawa J, Stevenson L, Moriguchi J, et al. Is intravenous glucocorticoid therapy better than an oral regimen for asymptomatic cardiac rejection? A randomized trial. J Am Coll Cardiol 1993;21:1142–4.

    Article  PubMed  CAS  Google Scholar 

  133. Park M, Starling R, Ratliff N, et al. Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection. J Heart Lung Transplant 1999;18:1224–7.

    Article  PubMed  CAS  Google Scholar 

  134. Costanzo-Nordin M, O’ Sullivan E, Hubbell E, et al. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): The Loyola experience. J Heart Lung Transplant 1989;8:288–95.

    CAS  Google Scholar 

  135. Macris M, Frazier O, Lammermeier D, Radovancevic B, Duncan J. Clinical experience with muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation. J Heart Lung Transplant 1989;8:281–7.

    CAS  Google Scholar 

  136. Sweeney M, Sinnott J, Cullison J, Weinstein S, Cardiac Transplant Team. The use of OKY3 for stubborn heart allograft rejection: An advance in clinical immunotherapy? J Heart Lung Transplant 1987;6:324–8.

    CAS  Google Scholar 

  137. Bristow M, Gilbert E, Renlund D, DeWitt C, Buronw N, O’Connell J. Use of OKT3 monoclonal antibody in heart transplantation: Review of the initial experience. J Heart Lung Transplant 1988;7:1–11.

    Google Scholar 

  138. Costanzo-Nordin M, Silver m, O’Connell J, et al. Successful reversal of acute cardiac allograft rejection with OKT3 monoclonal antibody. Circulation 1987;76 (suppl V):V-71–V-80.

    Google Scholar 

  139. Gilbert E, Dewitt C, Eiswirth C, et al. Treatment of refractory cardiac allograft rejeciton with OKT3 monoclonal antibody. Am J Med 1987;82:202–6.

    Article  PubMed  CAS  Google Scholar 

  140. Taylor D, Kfoury A, Pisani B, Hammond E, Renlund D. Antilymphocyte-antibody prophylaxis: Review of the adult experience in heart transplantation. Transplant Proc 1997;29 (suppl 8A):13S–15S.

    PubMed  Google Scholar 

  141. Kobashigawa J, Stevenson L, Moriguchi J, et al. Randomized study of high dose oral cyclosporine therapy for mild acute cardiac rejection. J Heart Lung Transplant 1989;8:53–8.

    CAS  Google Scholar 

  142. Haverty T, Sanders M, Sheahan M. OKT3 treatment of cardiac allograft rejection. J Heart Lung Transplant 1993;21:591–8.

    Google Scholar 

  143. Kirklin J, Bourge R, McGiffin D. Recurrent of persistent cardiac allograft rejection: Therapeutic options and recommendations. Transplant Proc 1997;29 (suppl 8A):40S–44S.

    PubMed  Google Scholar 

  144. Mentzer R, Jahania M, Lasley R, US Multicenter FK506 Study Group. Tacrolimus as a rescue immunosuppression after heart and lung transplantation. Transplantation 1998;65:109–13.

    Article  PubMed  CAS  Google Scholar 

  145. Pham S, Kormos R, Hattler B, et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 1996;111:764–72.

    Article  PubMed  CAS  Google Scholar 

  146. Armitage J, Dormos R, Fung J, et al. Preliminary experience with FK506 in thoracic transplantation. Transplantation 1990;52:164–7.

    Article  Google Scholar 

  147. Rinaldi M, Pellegrini C, Martinelli L, et al. FK506 effectiveness in reducing acute rejection after heart transplantation: A prospective randomized study. J Heart Lung Transplant 1997;16:1001–10.

    PubMed  CAS  Google Scholar 

  148. Meiser B, Uberfuhr P, Fuchs A, et al. Tacrolimus: A superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant 1997;16:795–800.

    PubMed  CAS  Google Scholar 

  149. Asante-Korang A, Boyle G, Webber S, Miller S, Fricker F. Experience of FK506 immune suppression in pediatric heart transplantation: A study of long-term adverse effects. J Heart Lung Transplant 1996;15:415–22.

    PubMed  CAS  Google Scholar 

  150. Yamani M, Starling R, Pelegrin D, et al. Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. J Heart Lung Transplant 2000;19:337–42.

    Article  PubMed  CAS  Google Scholar 

  151. Kirklin J, Bourge R, Naftel D, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): Initial clinical experience. J Heart Lung Transplant 1994;13:444–50.

    PubMed  CAS  Google Scholar 

  152. Taylor D, Ensley R, Olsen S, Dunn D, Renlund D. Mycophenolate mofetil (RS-61443): Preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant 1994; 13: 571–82.

    PubMed  CAS  Google Scholar 

  153. Ensley R, Bristow M, Olsen S, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993;56:75–82.

    Article  PubMed  CAS  Google Scholar 

  154. Costanzo-Nordin M, Grusk B, Silver M, et al. Reversal of recalcitrant cardiac allograft rejection with methotrexate. Circulation 1988;78 (suppl III):III-47–III-57.

    Google Scholar 

  155. Bourge R, Kirklin J, White-Williams C, et al. Methotrexate pulse therapy in the treatment of recurrent acute heart rejection. J Heart Lung Transplant 1992;11:1116–24.

    PubMed  CAS  Google Scholar 

  156. Hosenpud J, Hershberger R, Ratkovec R, et al. Methotrexate for the treatment of patients with multiple episodes of acute cardiac allograft rejection. J Heart Lung Transplant 1992;11:739–45.

    PubMed  CAS  Google Scholar 

  157. Ross H, Gullestad L, Pak J, Slauson S, Valantine H, Hunt S. Methotrexate of total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: A comparative study. J Heart Lung Transplant 1997;16:179–89.

    PubMed  CAS  Google Scholar 

  158. Costanzo M, Koch D, Fisher S, Heroux A, Kao W, Johnson M. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 1997;16:169–78.

    PubMed  CAS  Google Scholar 

  159. Bouchart F, Gundry S, Schaack-Gonzales J, et al. Methotrexate as rescue/adjunctive immunotherapy in infant and adult heart transplantation. J Heart Lung Transplant 1993;12:427–33.

    PubMed  CAS  Google Scholar 

  160. Salter M, Kirklin J, Bourge R, et al. Total lymphoid irradiation in the treatment of early or recurrent heart rejection. J Heart Lung Transplant 1992;11:902–12.

    PubMed  CAS  Google Scholar 

  161. Hunt S, Strober S, Hoppe R, Stinson E. Total lymphoid irradiation for treatment of intractable cardiac allograft rejection. J Heart Lung Transplant 1991;10:211–16.

    PubMed  CAS  Google Scholar 

  162. Keogh A, Morgan G, Macdonald P, Spratt P, Mundy J, McCosker C. Total lymphoid irradiation for resistant rejection after heart transplantation: Only moderate success medium-term. J Heart Lung Transplant 1996;15:231–3.

    PubMed  CAS  Google Scholar 

  163. Madden B, Backhouse L, McClosky D, Reynolds L, Tait D, Murday A. Total lymphoid irradiation as rescue therapy after heart transplantation. J Heart Lung Transplant 1996;15:234–8.

    PubMed  CAS  Google Scholar 

  164. Di Salvo T, Narula J, Cosimi A, Keck S, Dec G, Semigran M. Actinomycin D is an effective adjunctive immunosuppressive agent in recurrent cardiac allograft rejection. J Heart Lung Transplant 1995;14:955–62.

    Google Scholar 

  165. Stinson E, Dong E, Bieber C, Popp R, Shumway N. Cardiac transplantation in man II. Immunosuppressive therapy. J Thor Cardiovasc Surg 1969;58:326–43.

    CAS  Google Scholar 

  166. Partanen J, Nieminen M, Krogerus L, Harjula A, Manila S. Heart transplant rejection treated with plasmapheresis. J Heart Lung Transplant 1992; 11:301–5.

    PubMed  CAS  Google Scholar 

  167. Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclosphosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant 2001;20:316–21.

    Article  PubMed  CAS  Google Scholar 

  168. Costanzo-Nordin M, Hubbell E, O’Sullivan E, et al. Successful treatment of heart transplant rejection with photophoresis. Transplantation 1992;53:808–15.

    Article  PubMed  CAS  Google Scholar 

  169. Rose E, Barr M, Xu H, et al. Photochemotherapy in human heart transplant recipients at high risk for fatal rejection. J Heart Lung Transplant 1992; 11:746–50.

    PubMed  CAS  Google Scholar 

  170. Meiser B, Kur F, Reichenspurner H, et al. Reduction of the incidence of rejection by adjunct immunosuppression with photochemotherapy after heart transplantation. Transplantation 1994; 57:563–8.

    PubMed  CAS  Google Scholar 

  171. Dall’ Amico R, Livi U, Milano A, et al. Extracorporeal photochemotherapy as adjuvant treatment of heart transplant recipients with recurrent rejection. Transplantation 1995;60:45–9.

    Article  Google Scholar 

  172. Smith J, Ribakove G, Hunt A, et al. Heart retransplantation: the 25-year experience at a single institution. J Heart Lung Transplant 1995;14:832–9.

    PubMed  CAS  Google Scholar 

  173. Ensley R, Hunt S, Taylor D, et al. Predictors of survival after repeat heart transplantation. J Heart Lung Transplant 1992;11:S142–S158.

    PubMed  CAS  Google Scholar 

  174. McGoon M, Frantz R. Techniques of immunosuppression after cardiac transplantation. Mayo Clin Proc 1992;67:586–95.

    PubMed  CAS  Google Scholar 

  175. Griffith B, Hardesty R, Deeb G, Starzl T, Bahnson H. Cardiac transplantation with cyclosporin A and prednisone. Ann Surg 1982;196:324–9.

    Article  PubMed  CAS  Google Scholar 

  176. Kahan B. Immunosuppressive therapy with cyclosporine for cardiac transplantation. Circulation 1987;75:40–56.

    Article  PubMed  CAS  Google Scholar 

  177. Trento A, Griffith B, Hardesty R, Kormos R, Thompson M, Bahnson H. Cardiac transplantation: improved quality of survival with a modified immunosuppressive protocol. Circulation 1987;76 (suppl V):V-48–V-51.

    Google Scholar 

  178. Yacoub M, Alivizatos P, Khaghani A, Mitchell A. The use of cyclosporine, azathioprine and anithymocyte globulin with or without low-dose steroids for immunosuppression of cardiac transplant patients. Transplant Proc 1985;17:221–2.

    Google Scholar 

  179. Grattan M, Moreno-Cabral C, Starnes V, Oyer P, Stinson E, Shumway N. Eight-year results of cyclosporine-treated patients with cardiac transplants. J Thor Cardiovasc Surg 1990;99:500–9.

    CAS  Google Scholar 

  180. Esmore D, Spratt P, Keogh A, Chang V. Cyclosporine and azathioprine immunosuppression without maintenance steroids: A prospective randomized trial. J Heart Lung Transplant 1989;8:194–9.

    Google Scholar 

  181. Keogh A, Macdonald P, Mundy J, Chang V, Harvison A, Spratt P. Five-year follow-up of a randomized double-versus triple-drug therapy immunosuppressive trial after heart transplantation. J Heart Lung Transplant 1992;11:550–6.

    PubMed  CAS  Google Scholar 

  182. Kahan B. Cyclosporine. New Engl J Med 1989;321:1725–38.

    Article  PubMed  CAS  Google Scholar 

  183. Halloran P, Lui S. Chapter 12, Approved Immunosuppresants in Primer on Transplantation, DJ Norman and WN Suki, eds, The American Society of Transplant Physicians. 1998.

    Google Scholar 

  184. El Gamel S, Keevil B, Rhaman A, Campbell C, Derianiya A, Yonan A. Cardiac allograft rejection: Do trough cyclosporine levels correlate with the grade of histologic rejection? J Heart Lung Transplant 1997;16:268–74.

    PubMed  Google Scholar 

  185. Best N, Trull A, Tan K, Spiegelhalter D, Cary N, Wallwork J. Pharmacodynamics of cyclosporine in heart and heart-lung transplant recipients. Transplantation 1996;62:1429–35.

    Article  PubMed  CAS  Google Scholar 

  186. Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995;333:628–33.

    Article  PubMed  CAS  Google Scholar 

  187. Chan C, Maurer J, Cardella C, Cattran D, Pei Y. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation 1997;63: 1435–40.

    Article  PubMed  CAS  Google Scholar 

  188. White M, Pelletier G, Tan A, Jesina C, Carrier M. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine: Sandimmune versus the microemulsion Neoral in heart transplant recipients. J Heart Lung Transplant 1997;16:787–94.

    PubMed  CAS  Google Scholar 

  189. Valantine H. Neoral use in the cardiac transplant recipient. Transplant Proc 2000;32(3A suppl):27S–44S.

    Article  PubMed  CAS  Google Scholar 

  190. Eisen H, Hobbs R, Davis S, G, et al. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine-results at six months after transplantation. Transplantation 1999;68:663–71.

    Article  PubMed  CAS  Google Scholar 

  191. Taylor D, Barr M, Radonvancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: Decreased hyperlipi-demia and hypertension with tarcolimus. J Heart Lung Transplant 1999;18:336–45.

    Article  PubMed  CAS  Google Scholar 

  192. Myers B, Ross J, Newton L, Leutscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984;311:699–705.

    Article  PubMed  CAS  Google Scholar 

  193. Goldstein D, Zuech N, Sehgal V, Weinber A, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation. Transplantation 1997;63:664–8.

    Article  PubMed  CAS  Google Scholar 

  194. Scherrer U, Vissing S, Morgan B, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. New Engl J Med 1990;323:693–9.

    Article  PubMed  CAS  Google Scholar 

  195. de Groen P, Aksamit A, Rakela J, Forbes G, Krom R. Central nervous system toxicity after liver transplantation: The role of cyclosporine and cholesterol. New Engl J Med 1987;317:861–6.

    Article  PubMed  CAS  Google Scholar 

  196. Adams D, Gunson B, Honigsberger L, et al. Neurological complications following liver transplantation. Lancet 1987;1:949–51.

    Article  PubMed  CAS  Google Scholar 

  197. Lane R, Roche S, Leung A, Greco A, Lange L. Cyclosporine neurotoxicity in cardiac transplant recipients. J Neurol, Neurosurg, and Psych 1988;51:1434–7.

    Article  CAS  Google Scholar 

  198. Cooper D, Novitzky D, Davis L, et al. Does central nervous system toxicity occur in transplant patients with hypocholesterolemia receiving cyclosporine? J Heart Lung Transplant 1989;8:211–14.

    Google Scholar 

  199. Lin H, Rocher L, McQuillan M, Schmaltz S, Palella T, Fox I. Cyclosporine-induced hyperuricemia and gout. New Engl J Med 1989;321:287–92.

    Article  PubMed  CAS  Google Scholar 

  200. Kobashigawa J, Miller L, Renlund D, et al. A randomized, active-controlled trial ofmycopheno-late mofetil in heart transplant recipients. Transplantation 1999;66:507–15.

    Article  Google Scholar 

  201. Keogh A, Bourge R, Costanzo M, et al. Three year results of the double-blind randomized multi-center trial of mycophenolate mofetil in heart transplant patients (abstract). J Heart Lung Transplant 1999;18:53.

    Google Scholar 

  202. Meiser B, Pfeiffer M, Schmidt D, et al. Combination therapy with tracrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999;18:143–9.

    Article  PubMed  CAS  Google Scholar 

  203. Yamani M, Starling R, Goormastic M, et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000;69:2326–30.

    Article  PubMed  CAS  Google Scholar 

  204. Taylor D, Sharma R, Kfoury A, Renlund D. Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from mycophenolate mofetil to azathioprine. Clin Transplant 1999;13:296–9.

    Article  PubMed  CAS  Google Scholar 

  205. Halloran P, Lui S. Approved Immunosuppressants. Chapter 12 in Primer on Transplantation, DJ Norman and WN Suki, eds. American Society of Transplant Physicians. 1998.

    Google Scholar 

  206. Renlund D, O’Connell J, Bristow M. Early rejection prophylaxis in heart transplantation: Is cytolytic therapy necessary? J Heart Lung Transplant 1989;8:191–3.

    CAS  Google Scholar 

  207. Alonso-Poupon L, Serrano-Fiz S, Rubio J, et al. Efficacy of low-dose OKT3 as cytolytic induction therapy in heart transplantation. J Heart Lung Transplant 1995;14:136–42.

    Google Scholar 

  208. Mentis A, Powell A, Novick R, et al. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts. J Heart Lung Transplant 1992;11:569–76.

    Google Scholar 

  209. Kobashigawa J, Stevenson L, Brownfleld E, et al. Does short-course induction with OKT3 improve outcome after heart transplantation? A randomized trial. J Heart Lung Transplant 1993;12:250–8.

    Google Scholar 

  210. Griffith B, Kormos R, Armitage J, Dummer J, Hardesty R. Comparative trial of immunoprophy-laxis with RATG versus OKT3. J Heart Transplant 1990;9:301–5.

    PubMed  CAS  Google Scholar 

  211. Kormos R, Herlan D, Armitrage J, et al. Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation. J Heart Transplant 1990;9:1–10.

    PubMed  CAS  Google Scholar 

  212. Hegewald M, O’Connell J, Renlund D, et al. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation. J Heart Lung Transplant 1989;8:303–10.

    CAS  Google Scholar 

  213. Starnes V, Oyer P, Steinson E, Dein J, Shumway N. Prophylactic OKT3 used as induction therapy for heart transplantation. Circulation 1989;80(suppl III):III-79–III-83.

    Google Scholar 

  214. Kawaguchi A, Szentpetery S, Mohanakumar T, Barnhart G, Lower R. Effects of prophylactic rabbit anithymocyte globulin in cardiac allograft recipients treated with cyclosporine. J Heart Lung Transplant 1987;6:214–17.

    CAS  Google Scholar 

  215. O’Connell J, Renlund D, Hammond E, et al. Sensitization to OKT3 monoclonal antibody in heart transplantation: Correlation with early allograft loss. J Heart Lung Transplant 1991;10:217–22.

    PubMed  Google Scholar 

  216. Schroeder T, First M, Hurtubise P, et al. Immunologic monitoring with orthoclone OKT3 therapy. J Heart Lung Transplant 1989;8:371–80.

    CAS  Google Scholar 

  217. Costanzo-Nordin M, O’Sullivan J, Johnson M, et al. Prospective randomized trial of OKT3-versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation. J Heart Lung Transplant 1990;9:306–15.

    CAS  Google Scholar 

  218. Swinnen L, Costanzo-Nordin M, Fisher S, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990;323:1723–8.

    Article  PubMed  CAS  Google Scholar 

  219. Beniaminovitz A, Itsecu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monclonal antibody. New Engl J Med 2000;342: 613–19.

    Article  PubMed  CAS  Google Scholar 

  220. Van Gelder T, Balk A, Jonkman F, et al. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. Transplantation 1996;62:51–5.

    Article  PubMed  Google Scholar 

  221. Sayegh M, Turka L. The role to T-cell costimulatory activation pathways in transplant rejection. N Engl J Med l998;338.

    Google Scholar 

  222. Strom T, Ettenger R. Investigational immunosuppressants: Biologies. Chapter 14 in Primer on Transplantation, DJ Norman and WN Suki, eds. American Society of Transplant Physicians. 1998.

    Google Scholar 

  223. Miller L. Steroid withdrawl in heart transplantation: Editorial. J Heart Lung Transplant 1992;11:410–13.

    Google Scholar 

  224. Renlund D, O’Connell J, Gilbert E, Watson F, Bristow M. Feasibility of discontinuation of corti¬costeroid maintenance therapy in heart transplantation. J Heart Transplant 1987;6:71–8.

    PubMed  CAS  Google Scholar 

  225. Taylor D, Bristow M, O’Connell J, et al. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant 1996;15:1039–46.

    PubMed  CAS  Google Scholar 

  226. Pritzker M, Lake K, Reutzel T, et al. Steroid-free maintenance immunotherapy: Minneapolis Heart Institute experience. J Heart Lung Transplant 1992;11:415–20.

    PubMed  CAS  Google Scholar 

  227. Kobashigawa J, Stevenson L, Brownfield E, et al. Initial success of steroid weaning late after heart transplantation. J Heart Lung Transplant 1992;11:428–30.

    PubMed  CAS  Google Scholar 

  228. Miller L, Wolford T, McBride L, Peigh P, Pennington D. Successful withdrawal of corticosteroids in heart transplantation. J Heart Lung Transplant 1992;11:431–4.

    PubMed  CAS  Google Scholar 

  229. Olivari M, Jessen M, Baldwin B, et al. Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation. J Heart Lung Transplant 1995;14:127–35.

    PubMed  CAS  Google Scholar 

  230. Keogh A, Macdonald P, Narvison A, Richens D, Mundy J, Spratt P. Initial steroid-free versus steroid-based maintenance therapy and steroid withdrawal after heart transplantation: Two views of the steroid question. J Heart Lung Transplant 1992;11:421–7.

    PubMed  Google Scholar 

  231. Kobashigawa J, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621–7.

    Article  PubMed  CAS  Google Scholar 

  232. Maggard M, Ke D, Want T, et al. Effects of pravastatin on chronic rejection of rat cardiac allografts. Transplantation 1998;65:149–55.

    Article  PubMed  CAS  Google Scholar 

  233. Keogh A, Macdonald P, Kann A, Aboyoun C, Spratt P, Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000;19:528–37.

    Article  Google Scholar 

  234. Ballantyne C. Statins after cardiac transplantation: Which statin, what dose, and how low should we go? J Heart Lung Transplant 2000;19:515–17.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Heart Failure and Cardiac Transplantation Center, Massachusetts General Hospital, Boston, MA, USA

    Thomas G. Di Salvo MD, MPH & G. William Dec MD

Authors
  1. Thomas G. Di Salvo MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. William Dec MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Heart Failure & Transplantation Service, Harvard Medical School, Bigelow 645, 55 Fruit Street, Boston, Massachusetts, 02114, USA

    G William Dec M.D.

  2. Heart Failure/Transplantation Center, Hahnemann University School of Medicine, Broad and Vine Streets, Mail Stop 115, Philadelphia, Pennsylvania, 19102, USA

    Jagat Narula M.D., Ph.D. (Director) (Director)

  3. Department of Cardiology, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, Roure 80, 25198, Lleida, Spain

    Manel Ballester M.D. (Chairman) (Chairman)

  4. Nuclear Medicine Department, Hospital de Sant Pau, Autonomous University of Barcelona, Pare Claret 167, 08025, Barcelona, Spain

    Ignasi Carrio M.D. (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Di Salvo, T.G., Dec, G.W. (2001). Clinical Diagnosis and Management of Cardiac Allograft Rejection and Maintenance Immunosuppression. In: Dec, G.W., Narula, J., Ballester, M., Carrio, I. (eds) Cardiac Allograft Rejection. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1649-1_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1649-1_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5659-2

  • Online ISBN: 978-1-4615-1649-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation